Source comparison
Receptor Mechanisms: GHRH vs Ghrelin Pathway Activation
Ipamorelin binds selectively to the ghrelin receptor (growth hormone secretagogue receptor 1a) on somatotroph cells in the anterior pituitary. This triggers intracellular calcium mobilisation and cAMP-dependent signalling, resulting in pulsatile HGH secretion
This comparison does not assign a generated winner or score.
- Ipamorelin binds selectively to the ghrelin receptor (growth hormone secretagogue receptor 1a) on somatotroph cells in the anterior pituitary. This triggers intracellular calcium mobilisation and cAMP-dependent signalling, resulting in pulsatile HGH secretion that mirrors endogenous growth hormone release patterns. Selectivity is the defining feature. Ipamorelin does not cross-activate ACTH receptors (no cortisol spike) or lactotroph cells (no prolactin elevation), which earlier GHRPs like GHRP-6 and hexarelin were known to do. The pulse amplitude averages 2–3× baseline in controlled studies, with duration limited by the compound's 2-hour half-life.
- Tesamorelin operates upstream. It's a synthetic GHRH analogue. 44 amino acids, modified to resist enzymatic degradation. That binds to GHRH receptors in the hypothalamus. This stimulates sustained release of endogenous GHRH, which then activates pituitary somatotrophs. The sustained component matters: while ipamorelin produces sharp peaks, tesamorelin generates elevated baseline HGH over 6–8 hours. Combine the two and you create overlapping activation. Pulsatile surges layered on elevated baseline levels. Which alters downstream IGF-1 production and shifts hepatic glucose metabolism in ways single-agent protocols do not replicate.
- Our experience with dual-pathway protocols shows the receptor synergy is non-redundant. Activating both GHRH and ghrelin receptors simultaneously recruits different intracellular signalling cascades (PKA vs PKC pathways), which compounds the anabolic signal without proportionally increasing side effect risk. Named trials like GHRH-GHRP combination studies from Emory University School of Medicine demonstrated 40% greater IGF-1 elevation with dual agonism compared to either agent alone at equivalent HGH peak levels.